Evidence map›Paper›PMID 39331072›Full record

ReviewHerz2024

Cannabinoids and the heart-a psychiatrist's perspective.

Johannes Kramer, Gabi Koller, Oliver Pogarell

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Johannes KramerKlinik und Poliklinik für Psychiatrie und Psychotherapie, LMU Klinikum, LMU München, Nußbaumstr. 7, 80336, Munich, Germany.
Gabi KollerKlinik und Poliklinik für Psychiatrie und Psychotherapie, LMU Klinikum, LMU München, Nußbaumstr. 7, 80336, Munich, Germany.
Oliver PogarellKlinik und Poliklinik für Psychiatrie und Psychotherapie, LMU Klinikum, LMU München, Nußbaumstr. 7, 80336, Munich, Germany. oliver.pogarell@med.uni-muenchen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The partial legalization of cannabis in Germany in 2024 will affect both medical and recreational use of cannabis. Tetrahydrocannabinol (THC), the main psychoactive component of the cannabis plant, influences heart rate and blood pressure through the endocannabinoid system. Acute and chronic use can pose cardiovascular risks. There is evidence of a link between cannabis use and cardiovascular events such as stroke and myocardial infarction, although studies show conflicting results. The non-psychoactive cannabidiol (CBD) could have anti-inflammatory and antioxidant effects. Smoking cannabis poses additional cardiovascular risks similar to tobacco. Given these risks, cardiologists should routinely ask their patients about possible cannabis use and inform them about the potential cardiovascular dangers. The article also highlights the psychiatric risks of cannabis use, including dependence and psychosis, and emphasizes the need for interdisciplinary collaboration between cardiologists and psychiatrists to effectively manage cannabis-related health problems.

Indexed as

CannabinoidsCardiovascular DiseasesGermanyHumansMarijuana AbusePsychiatristsPsychiatryCannabinoidsCannabisCardiovascular healthMyocardial infarctionPsychosisStroke

Identifiers

PMID39331072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.